The trick: Lab Not Field
The AI cancer 'treatment' is one plant compound that worked alongside an existing drug on cancer cell clumps in a dish.
No mice, no patients yet.
A new AI produced a cancer treatment that stunned scientists.
Before you read on. Your call?
TRUE, BUT
23
UCLA's MAESTRO ranked 3,592 natural products as add-ons to enzalutamide; 23 of 150 picks showed synergy in 3D prostate cancer spheroids, and berberine stood out. The paper calls it an in vitro hit. Animal studies come next.
There’s more to this story.
Membership opens the full investigation, the strongest counterargument and what to do with what you’ve learned.
30 days free, then A$89 a year. Payment card required. Cancel before the trial ends to avoid the first charge.
Review my 30-day free trial →- At sign-up: 30 days free. Payment card required. One introductory trial per customer.
- Your trial ends 30 days after you start. Unless you cancel before then in Account → Manage subscription, we charge A$89 for the first year. It renews automatically at A$89/yr until cancelled.
- You can ask for a full refund within 14 days after any annual payment, renewals included, with no reason needed, by emailing hello@bskiller.com. This voluntary refund does not limit your rights under the Australian Consumer Law.
By starting your trial, you agree to the Terms.
BS Killer is published by Inferno Tech Pty Ltd, ABN 27 647 413 474.
Get tomorrow’s check free by email.
Couldn't check your access. That's on us.
The trick has a name
We call it Lab Not Field: it works in the test conditions, not the deployed ones. You'll see it again. Learn to spot it →
Receipts
- Supports uclahealth.org:
The researchers used the platform to evaluate 3,592 natural products for their potential to work with enzalutamide.
- Context uclahealth.org:
a drug originally discovered and developed at UCLA that is commonly used to treat advanced prostate cancer
- Context uclahealth.org:
The system identified 150 high-confidence candidates for testing in 3D prostate cancer spheroids.
- Context uclahealth.org:
Of the 150 compounds tested, 23 showed evidence of synergy with enzalutamide
- Supports uclahealth.org:
Further testing identified berberine, a naturally occurring compound found in several plants, as a particularly promising candidate.
- Refutes uclahealth.org:
The researchers plan to further evaluate the combination in patient-derived tumor models and animal studies.
- Supports uclahealth.org:
MAESTRO could substantially accelerate this process.
- Supports uclahealth.org:
berberine and enzalutamide showed consistent synergy across four prostate cancer models with different mechanisms of treatment resistance
- Refutes ebi.ac.uk:
berberine-enzalutamide as an in vitro combination hit that re-sensitized resistant prostate cancer cells to AR blockade
- Context ebi.ac.uk:
can prioritize and experimentally evaluate drug-combination hypotheses at an early stage of discovery.
- Context eutils.ncbi.nlm.nih.gov:
This work introduces a hybrid in silico and in vitro lead discovery platform
Open the Receipts Pack → What each source proves, every figure traced, and what would change our verdict.
